Objective: Screening for differentially expressed microRNAs in the serum of normal pregnancy and preeclampsia patients, and combined with hematological and indicators analysis, in order to provide certain reference value for clinical diagnosis of early preeclampsia. Methods: Download the microRNA dataset related to preeclampsia from the GEO database, screen for differentially expressed microRNAs using the DESeq [1.36.0] package, and validate them in serum samples. Collecting serum from 37 pregnant women with preeclampsia (PE group) who had normal antenatal examinations and delivered at Nanjing Maternity and Child Health Care Hospital from January 2024 to July 2024, as well as 33 age and gestational week matched normal pregnant women (control group) who had antenatal examinations at the same period in our hospital. Total microRNA was extracted from serum samples and the expression of microRNA in the two groups of sera was detected by quantitative fluorescence PCR. At the time, hematological parameters and biochemical test data were collected. Independent sample t-test was used to analyze the differences in test results, and chi-square test was used to compare the differences in complications between the two groups. In addition, the value of the screened microRNAs and their combination with blood biochemical indicators in predicting and diagnosing preeclampsia was by using the receiver operating characteristic (ROC) curve. Results: Download the GEO database for the dataset GSE234611 of microRNAs expressed in the peripheral blood of early-onsetreeclampsia patients and normal pregnant women, and the dataset GSE118578 of microRNAs in primary hypertension patients and normal individuals, ?differential expression analysis was performed on the two datasets using the DESeq2 [1.36.0] package, and four commonly different expressed miRNAs were found between the two datasets (hsa-miR-106b-5p, hsa-mi-24-3p, hsa-miR-451a, and hsa-miR-92b-3p ). Further detection of serum samples found that the expression of hsa-miR-451a and hsa-miR-10b-5p in the PE group was significantly increased (P<0.05), while the expression of hsa-miR-24-3 and hsa-miR-92b-3p showed no significant difference (P>0.05).Hematological and biochemical indicators were compared between the two groups, and it was found that the PE group had significantly lower platelet count and neutil/lymphocyte ratio than the control group, while the lymphocyte count, mean platelet volume, uric acid, and homocysteine were significantly higher (P<0.05). ROC curve analysis showed that the area under the curve (AUC) for predicting preeclampsia diagnosis using serum hsa-miR451a, hsa-miR-106b-5p, uric acid, and homocysteine were 0.827, 0.931, 0.801, and 0.704, respectively; The AUC of combined diagnosis of hsa-miR-451a, uric acid and homocysteine was 0.908, with a sensitivity of 72.22% and a specificity of 94.12%; the AUC of combined of hsa-miR-106b-5p, uric acid and homocysteine was 0.941, with sensitivity of 94.44% and a specificity of 88.23%. The incidence of adverse pregnancy complications in the PE group was significantly higher than that in the control group (P<0.05). Conclusion：Combined detection of hsa-miR-106b-5p, uric acid, and homocysteine in serum has predictive and diagnostic value for preeclampsia.